The EFSA Panel concluded that rebaudioside M produced via a new enzymatic process using genetically modified E. coli enzymes raises no safety concerns. Because no viable cells, DNA, or significant enzyme residues remain, and its physicochemical profile matches approved Reb M, previous toxicological safety data applies, supporting a distinct new food additive entry.

The EFSA Panel concluded that chemically synthesized cannabidiol (≥98% purity) in MCT oil is safe as a novel food supplement for adults over 25—excluding pregnant, breastfeeding, or medicated individuals—at a safe maximum intake of 2 mg per day.

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on S-acetyl glutathione (SAG) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.

EFSA has published its scientific opinion on the safety assessment of lacto-N-triose II (LNTri II) as a novel food. The Panel concluded that LNTri II does not raise safety concerns under the proposed conditions of use and use levels.

In H1 2026, the EU approved 8 food additive modifications, validated 5 dossiers, and published 9 scientific opinions. While new plant- and microorganism-derived additives are gaining interest, modification requests remain dominant. Amid strict upcoming EFSA guidance revisions, applicants must ensure complete, robust dossiers to ensure efficient market authorization.

Based on publicly available information from the Open EFSA and regulations issued by the European Commission, CIRS conducted a statistical analysis of the EU Novel Food (NF) approval dynamics in the first half of 2026 for enterprise reference.

Recently, the European Commission’s novel food status has updated the information regarding S-adenosyl-L-methionine disulfate tosylate (also referred to as Sadenosyl-L-methionine disulfate p-toluenesulfonate). According to the latest novel food status, this ingredient has now been recognized as a novel food.

The food enzyme amidase (acylamide amidohydrolase, EC 3.5.1.4) is produced with the genetically modified Escherichia coli strain SP-a by c-LEcta GmbH. The genetic modifications did not give rise to safety concerns.

To help companies clearly understand the international compliance status of NMN, CIRS Group will summarize the application approval status of NMN in the EU, the US, and Australia for reference.

As of March 31, 2026, based on publicly available information from the EU information retrieval platform (Open EFSA), CIRS has performed a statistical review of novel food (NF) application trends in the European Union (EU) for the first quarter of 2026.